RUNX1 and neoplasm: Further investigations have solidified RUNX1's predominantly tumor-suppressive capacity in ER+ breast cancer by counterbalancing the estrogen-driven suppression of AXIN1, an integral component of the Wnt/β-catenin signaling pathway 18.